Tailoring Treatment in Colorectal Cancer
Recruiting · NCT05401318 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Akershus
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients. With this, the investigators aim to develop a novel predictive biomarker of immunotherapy response, by testing combinations of chemotherapies and chimeric antigen receptor (CAR) T cells. Critically, this affects a large subgroup of patients currently not considered to benefit from such treatment. To support the hypothesis, the project will make use of cutting-edge, cell-based functional diagnostics. Individual patients' cancer cells will be screened against a panel of chemotherapies and targeted therapies including CAR T cells, to assess the optimal combination of therapies to induce immunotherapy efficacy in otherwise unresponsive CRC.
Who can take part
Inclusion criteria
- Histologically confirmed colorectal cancer scheduled for curative surgery and standard clinical follow-up.
Exclusion criteria
- \- Unable/unwilling to sign the informed consent form.
Where it is running
1 location listed.
- Akershus University Hospital - Lørenskog, Akershus, Norway